|  Keyword Search
| Date | Title | | | 12/21/06 | Nastech Reports Positive PYY Nasal Spray Clinical Trial Data and Will Advance Obesity Clinical Program in 2007| Trial Demonstrates Both Intravenous and PYY Nasal Spray
Produce Satiety and Calorie Reduction
BOTHELL, Wash., Dec. 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported positive results from a dose
ranging study designed to evaluate the pharmacokinetic parameters, appetite,
food intake and safety of various doses of Nastech's proprietary PYY(3-36)
nasal spray in obese subjects. The study identified doses for a long... |
|  | | 12/06/06 | Nastech Announces Positive Phase 1 Clinical Results of Insulin Nasal Spray Compared to Exubera(R) Inhalation Powder and NovoLog(C) Insulin Aspart Injection| Study shows Insulin Nasal Spray provides the fastest insulin response which
may be especially useful for type 2 diabetic patients
BOTHELL, Wash., Dec. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced results from a placebo controlled,
dose-escalation, cross-over Phase 1 study of Nastech's proprietary insulin
nasal spray formulations, NovoLog insulin aspart (rDNA origin) injection and
Exubera (insulin human [rDNA origin]) Inhala... |
| | | 12/04/06 | Nastech Pharmaceutical Company Inc. Provides Update on Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today provided a progress report on the
significant clinical development program currently being conducted and planned
for the Parathyroid Hormone (PTH1-34) Nasal Spray, which is under development
for the treatment of osteoporosis. Nastech also provided information with
regard to an amendment to the contract with Procter & Gamble Pharmaceuticals,
Inc., a division of The Procter &... |
| | | 12/04/06 | Nastech to Present at BMO Capital Markets Focus on Healthcare Conference| BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BMO
Capital Markets Focus on Healthcare Conference on Wednesday, December 6, 2006
at 1:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to reg... |
| | | 11/08/06 | Nastech RNAi Webinar Scheduled for Thursday, November 9, 2006, at 10:30 a.m. Eastern Time| Emerging RNAi Therapeutics Programs and Delivery Technology to be
Presented by Steven C. Quay, M.D., Ph.D., Chairman, President and CEO
BOTHELL, Wash., Nov. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting a Webinar to discuss the science
of RNA interference (RNAi), its emerging siRNA therapeutics programs and siRNA
drug delivery technology. Details follow:
What: Webinar on the science of RNAi and the Company's RNAi ... |
| | | 11/08/06 | Nastech Licenses RNAi Intellectual Property and Technology from City of Hope| Novel Dicer-Substrate RNAi Technology Could Offer Increased Potency
for Drug Development as Compared to Conventional RNAi Technology
BOTHELL, Wash. and DUARTE, Calif., Nov. 8 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
entered into a license agreement with City of Hope for rights to Dicer-
Substrate RNA interference (RNAi) intellectual property and technology.
Nastech obtained exclusive rights to five undisclo... |
| | | 11/02/06 | Nastech Announces Presentation of Scientific Abstracts at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting| Study Demonstrating that Nastech's Calcitonin-Salmon Nasal Spray is
Bioequivalent to Novartis' Miacalcin(R) (Calcitonin-Salmon) Nasal Spray and
Nastech's Insulin Nasal Spray Formulation Screening Results Presented
BOTHELL, Wash., Nov. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the presentation of two abstracts this
week at the American Association of Pharmaceutical Scientists Annual Meeting
in San Antonio, Texas. The abstrac... |
| | | 11/01/06 | Nastech Announces Third Quarter 2006 Financial Results| BOTHELL, Wash., Nov. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the three-
and nine-month periods ended September 30, 2006.
Revenue for the three months ended September 30, 2006 was $5.5 million,
compared to $1.2 million for the prior year period. Revenue for the nine
months ended September 30, 2006 was $23.7 million, compared to $6.2 million
for the prior year period. Revenue for 2006 includes approximate... |
| | | 10/31/06 | Nastech Pharmaceutical Company Inc. to Host Webinar on Its Emerging RNAi Therapeutics Programs and siRNA Delivery Technology| - Steven C. Quay, M.D., Ph.D., Chairman, President and CEO, to Present on
Thursday, November 9, 2006 -
BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will host a Webinar
concerning its emerging siRNA therapeutics programs and siRNA drug delivery
technology. Steven C. Quay, M.D., Ph.D., Chairman, President and CEO will
present at the event.
What: RNAi webinar on the science a... |
| | | 10/30/06 | Nastech to Present at Rodman & Renshaw Healthcare Conference| BOTHELL, Wash., Oct. 30 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Rodman
& Renshaw Healthcare Conference on Tuesday, November 7, 2006 at 12:45 p.m.
Eastern Time at the New York Palace Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and do... |
| | | 10/25/06 | Nastech to Release Third Quarter Financial Results and Host Webcast on Wednesday, November 1, 2006| BOTHELL, Wash., Oct. 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its third quarter financial
results will be released on Wednesday, November 1, 2006 after the Nasdaq
National Market System closes. Management will host a conference call with
investors and financial analysts to discuss these results and to provide an
update to its clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the liv... |
| | | 10/19/06 | Nastech Files Shelf Registration Statement| BOTHELL, Wash., Oct. 19 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has filed a shelf
registration statement on Form S-3 with the U.S. Securities and Exchange
Commission (SEC), pursuant to which Nastech may issue common stock from time
to time, up to an aggregate of $125 million. While the Company has no current
plans to access the capital markets, the shelf registration statement, once
declared effective by the SEC, would allow ... |
| | | 09/29/06 | Nastech Provides Calcitonin Salmon Nasal Spray Complete Response to FDA| In Vitro Testing Demonstrated no Evidence of Calcitonin-Preservative
Interaction or Calcitonin Aggregation Differences Due to Preservatives
BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today it has submitted a complete
response to the FDA's Office of Generic Drugs regarding the potential for
immunogenicity that might result from a possible interaction between
calcitonin-salmon and chlorobutanol, the preserv... |
| | | 09/29/06 | Nastech Pharmaceutical Named One of the Pacific Northwest's Fastest Growing Life Sciences Companies in Deloitte's Technology Fast 50 Program| BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) has been named to Deloitte's prestigious
Technology Fast 50 Program for the Pacific Northwest, a ranking of the 50
fastest growing technology, media, telecommunications and life sciences
companies in Washington, Oregon and Idaho by Deloitte & Touche USA LLP, one of
the nation's leading professional services organizations. Rankings are based
on the percentage revenue growth during ... |
| | | 09/26/06 | Nastech Receives $1.9 Million National Institute of Health-R01 Grant for Development of RNAi Therapeutics to Prevent and Treat Influenza| BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the National Institute of
Allergy and Infectious Diseases (NIAID), a division of the National Institutes
of Health (NIH), awarded the Company a $1.9 million Research Project (R01)
grant. This award combined with an earlier SBIR Phase 1 Small Business
Innovation Research (SBIR) grant award brings total program funding to
approximately $2.3 million from the NIH that ... |
| | | 09/26/06 | Nastech to Host 2006 Analyst and Institutional Investor Day| BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional
investor day in New York City on Wednesday, October 4, 2006 from
12:00 p.m. -- 3:00 p.m. Eastern Time at the InterContinental The Barclay New
York, on 111 East 48th Street. The event will feature presentations from
Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer
of Nastech, and Paul H. Johnson, Ph.D., Senior Vice... |
| | | 09/21/06 | Nastech to Present at UBS Global Life Sciences Conference| BOTHELL, Wash., Sept. 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the UBS
Global Life Sciences Conference on Tuesday, September 26, 2006 at 8:30 a.m.
Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any necess... |
| | | 09/19/06 | Nastech Initiates Clinical Development of Rapid Acting Insulin Nasal Spray for Diabetes| - Phase I pharmacokinetic study to compare Nastech's intranasal insulin to injectable insulin and Exubera(R) (insulin human [rDNA origin]) Inhalation Powder -BOTHELL, Wash., Sept 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the initiation of a Phase I
pharmacokinetic study designed to evaluate the safety, bioavailability and
glucose response of Nastech's proprietary, rapid acting intranasal insulin
formulation. ... |
| | | 08/29/06 | Nastech Awarded Development Grant for RNAi Therapeutics to Prevent and Treat Influenza| Funding provided by the National Institutes of Health
BOTHELL, Wash., Aug. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the National Institute of
Allergy and Infectious Diseases (NIAID), a division of the National Institutes
of Health (NIH), awarded the company a Phase 1 Small Business Innovation
Research (SBIR) grant. This award will be used to further develop the
Company's small-interfering RNA (siRNA) therapeutics t... |
| | | 08/14/06 | Nastech Initiates Dose Ranging Study of PYY(3-36) Nasal Spray for Obesity| BOTHELL, Wash., Aug. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the initiation of a dose ranging
study designed to evaluate the pharmacokinetic parameters, appetite, food
intake and safety of various doses of Nastech's proprietary PYY(3-36) nasal
spray in obese subjects. The objective of the study is to identify a dose or
doses which would be appropriate for further study in a long-term Phase II
efficacy and safety clinical trial.
... |
| | | 08/02/06 | Nastech Announces Second Quarter 2006 Financial Results| Quarterly revenue increased more than 600% over prior year to $11.4 million,
Cash and investments increased to $63.3 million
BOTHELL, Wash., Aug. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the three-
and six-month periods ended June 30, 2006.
Revenue for the three months ended June 30, 2006 was $11.4 million,
compared to $1.6 million for the three months ended June 30, 2005. Revenue
for the s... |
| | | 07/25/06 | Nastech Announces the Issuance of a Key Patent Directed to Using PYY by Any Administration Route to Treat Obesity| BOTHELL, Wash., July 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of a patent from the
United States Patent and Trademark Office relating to treatment of obesity
through the use of Peptide YY (PYY), a naturally produced hormone associated
with the modulation of appetite in the brain. The Company is developing a
proprietary PYY nasal spray to treat obesity. U.S. Patent No. 7,081,239
titled "Methods for manipulating upper ... |
| | | 07/24/06 | Nastech to Release Second Quarter Financial Results and Host Webcast on Wednesday, August 2, 2006| BOTHELL, Wash., July 24 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its second quarter financial
results will be released on Wednesday, August 2, 2006 after the Nasdaq
National Market System closes. Management will host a conference call with
investors and financial analysts to discuss these results and to provide an
update to its clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the live c... |
| | | 07/13/06 | Nastech Pharmaceutical Company Receives FDA Communication Concerning Calcitonin-Salmon Nasal Spray| BOTHELL, Wash., July 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that written notification from the
FDA was received on July 10, 2006 stating that Nastech's abbreviated new drug
application (ANDA) for intranasal calcitonin-salmon is not approvable at this
time. In a subsequent conference call on July 11, 2006, Nastech reviewed the
status of the ANDA with the FDA. The FDA expressed a concern relating to the
potential for immunogenici... |
| | | 06/27/06 | Nastech Scientific Abstracts Presented at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference| BOTHELL, Wash., June 27 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) presented two abstracts last week at the American
Association of Pharmaceutical Scientists National Biotechnology Conference in
Boston, Massachusetts.
The abstracts presented included:
*Development of a Glucagon-Like Peptide (GLP)-1 Intranasal Formulation
In vitro and in vivo results with a proprietary intranasal formulation of
GLP-1 were presented. GLP-1 is an incretin hor... |
| | | 06/26/06 | Nastech's Parathyroid Hormone (PTH1-34) Nasal Spray Demonstrated Similar Exposure Levels to Approved Injectable Product in Phase I Study in the Elderly| BOTHELL, Wash., June 26 /PRNewswire-FirstCall/ -- In a preliminary Phase I
clinical trial, a nasal spray dosage form of Parathyroid Hormone (PTH1-34)
developed by Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) provided
comparable exposure levels to the approved subcutaneous product, Forteo(R)
(teriparatide), in elderly subjects, according to data presented at ENDO(R)
2006, the 88th Annual Meeting of the Endocrine Society. If further development
is successful and leads to regulatory... |
| | | 06/26/06 | Nastech Pharmaceutical Company Inc. Enters into Development and License Agreement With Amylin Pharmaceuticals, Inc.| BOTHELL, Wash., June 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today an agreement with Amylin
Pharmaceuticals, Inc. to develop a nasal spray formulation of exenatide.
Preclinical studies of the formulation have been completed in preparation for
initiating studies to determine feasibility in human subjects.
Under terms of the agreement, Nastech will receive milestone payments and
royalties on product sales. If ... |
| | | 06/08/06 | Nastech Receives $7 Million Milestone Payment from Procter & Gamble for Advancement of Parathyroid Hormone (PTH1-34) Nasal Spray Program| BOTHELL, Wash., June 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the receipt of a $7 million
payment for attaining a development milestone under the Company's
collaboration with Procter & Gamble Pharmaceuticals, Inc., a division of The
Procter & Gamble Company (NYSE: PG), for development and commercialization of
Parathyroid Hormone (PTH1-34) nasal spray for treatment of osteoporosis. The
milestone will be recognized as revenue in the q... |
| | | 06/07/06 | Nastech Submits Investigational New Drug Application for PYY3-36 Nasal Spray to Treat Obesity| BOTHELL, Wash., June 7, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the submission of an
Investigational New Drug (IND) application to the U.S. Food and Drug
Administration for PYY3-36 (PYY) nasal spray, the company's lead
investigational product candidate for treatment of obesity. The filing of the
IND precedes the initiation of clinical studies in the United States.
The study included in the IND is designed t... |
| | | 06/06/06 | Nastech Enters Into Supply Agreement with Procter & Gamble for Parathyroid Hormone (PTH1-34) Nasal Spray| BOTHELL, Wash., June 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today an agreement with Procter & Gamble
Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG),
to manufacture and supply PTH1-34 nasal spray for the potential
commercialization of this investigational product for the treatment of
osteoporosis. This agreement further strengthens the collaboration between
the companies that began with the development and ... |
| | | 06/05/06 | Nastech to Present at Needham & Company Biotechnology and Medical Technology Conference| BOTHELL, Wash., June 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Needham & Company
Biotechnology and Medical Technology Conference on Wednesday, June 14, 2006 at
9:30 a.m. Eastern Time at The New York Palace Hotel in New York City. Steven
C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech, will provide a
corporate overview, including a review of the Company's product development
programs.
To access the live aud... |
| | | 05/25/06 | Nastech to Present at Friedman Billings Ramsey Growth Investor Conference| BOTHELL, Wash., May 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Friedman Billings Ramsey
Growth Investor Conference on Wednesday, May 31, 2006 at 11:15 a.m. Eastern
Time at the Grand Hyatt in New York City. Tim Duffy, Executive Vice President,
Marketing and Business Development of Nastech, will provide a corporate
overview, including a review of the Company's product development programs.
To access the live audio webcast... |
| | | 05/03/06 | Nastech Announces First Quarter 2006 Financial Results| BOTHELL, Wash., May 3 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended March 31, 2006.
Revenue for the three months ended March 31, 2006 was $6.7 million,
compared to $3.3 million for the three months ended March 31, 2005. The 2006
period included recognition of approximately $3.7 million in previously
deferred revenue related to our Merck collaboration that was terminated on
March 1, 2006, reimbur... |
| | | 04/28/06 | Pharmacokinetic Data for Nastech's Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile to Approved Injectable Product| BOTHELL, Wash., April 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) presents data today from a Phase I pharmacokinetic
study of Parathyroid Hormone (PTH1-34) nasal spray demonstrating a similar
pharmacokinetic profile to the approved subcutaneous product, Forteo(R)
(teriparatide). The data are being presented at the American Association of
Clinical Endocrinologists Annual Meeting in Chicago.
The Phase I study was conducted ... |
| | | 04/24/06 | Nastech to Release First Quarter Financial Results and Host Webcast on Wednesday, May 3, 2006| BOTHELL, Wash., April 24 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial
results will be released on Wednesday, May 3, 2006, after the Nasdaq National
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update on
the Company's clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in th... |
| | | 04/18/06 | Nastech to Present at UBS Global Specialty Pharmaceuticals Conference| BOTHELL, Wash., April 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the UBS Global Specialty
Pharmaceuticals Conference on Tuesday, April 25, 2006, at 1:00 p.m. Eastern
Time at The Grand Hyatt in New York City. Steven C. Quay, M.D., Ph.D.,
Chairman, President and CEO of Nastech, will provide a corporate overview,
including a review of the Company's product development programs.
To access the live audio webcast for this confer... |
| | | 03/16/06 | Nastech Presents Successful In Vitro and In Vivo Results with Its RNAi Therapeutics Program for Influenza| BOTHELL, Wash., March 16 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
the presentation of results demonstrating the effectiveness of the Company's
small interfering RNA (siRNA) therapeutics to broadly target and inhibit
influenza viral production at the 8th International Symposium on Respiratory
Viral Infections Conference.
In vitr... |
| | | 03/15/06 | Nastech Announces Fourth Quarter and Full Year 2005 Financial Results| BOTHELL, Wash., March 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, today reported
financial results for the fourth quarter and year ended December 31, 2005.
Revenue for the three months ended December 31, 2005 was $1.3 million,
compared to revenue of $1.5 million for the 2004 period. Revenue for the year
ended December 31, 2005 was $7.4 million,... |
| | | 03/15/06 | Nastech Pharmaceutical Company Inc. Announces Multi-Compound Agreement With Novo Nordisk A/S| BOTHELL, Wash., March 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that it has entered into a multi-compound, feasibility study agreement with
Novo Nordisk A/S (NYSE: NVO) with respect to certain Novo Nordisk therapeutic
compounds. Specific compounds and indications were not announced. Financial
and other terms were not disclosed.
... |
| | | 03/09/06 | Nastech to Release Fourth Quarter and Full Year 2005 Financial Results and Host Webcast on Thursday, March 16, 2006| BOTHELL, Wash., March 9 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that its fourth quarter and full year 2005 financial results will be released
on Thursday, March 16, 2006 after the Nasdaq National Market System closes.
Management will host a conference call with investors and financial analysts
to discuss these results and to provid... |
| | | 03/02/06 | Nastech Pharmaceutical Company Reschedules Conference Call to Discuss Reacquisition of PYY3-36 for the Treatment of Obesity From Merck| Conference Call to be Held at 8:30 a.m. Eastern Time on Friday, March 3, 2006
BOTHELL, Wash., March 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
that it will hold a conference call on Friday, March 3, 2006, at 8:30 a.m.
Eastern Time to discuss its reacquisition of PYY3-36 for the treatment of
obesity from Merck & Co., Inc.
Confer... |
| | | 03/02/06 | Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray for Treatment of Obesity and Will Advance Its Clinical Development| Mar 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
that it has reacquired its rights to PYY3-36 (PYY) nasal spray for treatment
of obesity from its collaboration partner, Merck & Co., Inc.
Nastech's agreement with Merck has terminated with receipt of Merck's
notice effective March 1, 2006. Merck's conclusio... |
| | | 02/28/06 | Nastech's Facility Approved for Commercial Manufacturing of Calcitonin-Salmon Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash., Feb. 28 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
the successful completion of the FDA's Pre-Approval Inspection (PAI) of its
Bothell, Washington facility. Successful completion of this PAI enables
Nastech to manufacture calcitonin-salmon nasal spray for commercial use upon
FDA approval of the Company's ANDA (Abbrevia... |
| | | 02/23/06 | Nastech to Present at Citigroup Healthcare Conference| BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, will be
presenting at the Citigroup Healthcare Conference on Monday, February 27, 2006
at 3:40 p.m. Eastern Time at The Mayflower Hotel in Washington, D.C. Gordon
Brandt, M.D., Executive V.P., Clinical Research and Medical Affairs of
Nastech, will provide a corporate overview, includi... |
| | | 02/23/06 | Nastech Acquires RNAi Therapeutics Program Targeting Influenza from Galenea| Exclusive Rights to Leading Technology and Intellectual Property to Develop
RNAi Therapeutics for Influenza and Respiratory Diseases
BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology based drug delivery technologies, announced today
the expansion of its RNAi therapeutics pipeline by initiating an RNAi
therapeutics program targeting influenza and respirato... |
| | | 02/07/06 | Nastech to Present at BIO CEO & Investor Conference| BOTHELL, Wash., Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, will be
presenting at the BIO CEO & Investor Conference on Wednesday, February 15,
2006, at 11:30 a.m. Eastern Time, at The Waldorf Astoria in New York City.
Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech, will
provide a corporate overview... |
| | | 02/01/06 | Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash. and CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in developing
therapeutics using advanced drug delivery technologies, and Procter & Gamble
Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG),
announced today a collaboration to develop and commercialize Nastech's
Parathyroid Hormone (PTH1-34) nasal spray for the treatment of osteoporosis.
Clinical and non-clinical studies on PTH1-34 nas... |
| | | 01/03/06 | Nastech Pharmaceutical Company Names Philip Ranker Chief Financial Officer| BOTHELL, Wash., Jan. 3 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
products and technologies, today announced today that Philip Ranker has been
named Chief Financial Officer and Corporate Secretary. Mr. Ranker has served
as Nastech's interim Chief Financial Officer and Corporate Secretary since
September 2005 and has been an integral part of Nastech's financial
organization and growth in his previous r... |
| |
|
|
|
